An Advocate General at the European Union has advised that a portion of a 2024 directive requiring manufacturers to fund the bulk of wastewater treatment costs should be annulled. The recommendation targets the part of the directive that would have obliged drug and cosmetics manufacturers to pay at least 80% of those costs.
The directive, which revised an earlier version and entered into force in early 2025, was framed as a response to concerns about pollution from urban wastewater and the presence of trace contaminants in water bodies across Europe. Officials behind the measure said it was intended to protect human health and the environment and to ensure cleaner rivers, lakes, groundwater, and coastal waters.
A key measure in the law is a required quaternary treatment stage at wastewater facilities. That stage targets the removal of micropollutants — substances largely produced by the pharmaceutical and cosmetics sectors. Under the directive’s timetable, member states were to make sure that companies contribute to programs addressing the waste they generate by December 2028.
Projections tied to the directive estimated substantial economic benefits from its implementation. Implementers expected the overall effort to produce savings of about $7.5 billion annually by 2040. The Advocate General’s recommendation, however, seeks to annul at least part of the requirement that producers cover the majority share of treatment costs.
If the Advocate General’s opinion is followed by the European Court of Justice, it could relieve pharmaceutical and cosmetics companies of a large financial obligation that national authorities had been preparing to collect. The affected industry sectors had been among the primary contributors targeted by the cost-sharing provision because of their links to micropollutant discharges.
For environmental and public-health policymakers, the recommendation raises questions about who will ultimately bear the cost of upgraded wastewater treatment and how quickly the quaternary treatment stage will be adopted across member states. The directive’s aims — cleaner waterways and reduced health risks from micropollutants — depend in practice on implementation at the national and municipal level.
The Advocate General’s written opinion is an influential step in proceedings before the European Court of Justice, but it is not itself a binding ruling. The Court typically takes the Advocate General’s analysis into account when issuing a final judgment, yet it can reach a different conclusion.
The source report did not provide the Advocate General’s full legal reasoning, details of the targeted provisions beyond the 80% cost-share element, or the identities of any parties that brought the challenge. It also did not report on potential reactions from member states, industry groups, or environmental organizations.
The directive’s notable technical requirement — the quaternary treatment stage — is aimed at reducing so-called micropollutants in treated wastewater. According to the directive text cited in the source, these micropollutants are mostly created by pharmaceuticals and cosmetics. Removing them was central to the directive’s environmental health goals.
The source material did not include technical specifications for the quaternary treatment, cost estimates for installing such systems at wastewater plants, or the estimated timeline for national compliance beyond the December 2028 deadline for company contribution programs.
A final outcome depends on the European Court of Justice’s ruling. The Advocate General’s recommendation will be filed with the Court and considered as the case proceeds. The source did not report on a schedule for the Court’s decision or on possible interim measures by member states while the litigation continues.
If the Court follows the Advocate General, member states and regulators may need to revisit national plans for financing upgraded treatment capacity and for meeting the directive’s environmental objectives. If the Court reaches a different conclusion, the original cost-sharing mechanism would remain in place, and implementation toward the December 2028 deadline would likely continue.
The source story set out the Advocate General’s recommendation and summarized the directive’s core aims, the quaternary treatment requirement, the 80% cost allocation for drug and cosmetics manufacturers, the December 2028 timeline for member-state measures, and the $7.5 billion annual savings projection for 2040. It did not provide the Advocate General’s full legal analysis, names of parties who challenged the rule, national reactions, industry statements, technical cost breakdowns, or a schedule for the Court’s final judgment.
Readers interested in the full legal text and the Advocate General’s full opinion can consult the documents published by the Court and the directive’s text as referenced in the original report. The source linked the Advocate General’s recommendation and the directive itself for further review.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.